Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805159 | 1.00 | HSD17B10 (0.42) | HSD17B10NPC1UCHL1ALDH1A1LMNA | |
| SCHEMBL22120434 | 0.95 | HSD17B10 (0.41) | HSD17B10NPC1UCHL1ALDH1A1LMNA | |
| SCHEMBL22128107 | 0.95 | HSD17B10 (0.41) | HSD17B10NPC1UCHL1ALDH1A1LMNA | |
| SCHEMBL24918232 | 0.90 | USP2 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL16224559 | 0.90 | USP2 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL2395205 | 0.90 | USP2 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL3626968 | 0.81 | HSD17B10 (0.46) | HSD17B10NPC1UCHL1ALDH1A1LMNA | |
| SCHEMBL10296209 | 0.81 | NPC1 (0.41) | HSD17B10NPC1UCHL1ALDH1A1LMNA | |
| SCHEMBL30439876 | 0.81 | HSD17B10 (0.40) | HSD17B10NPC1UCHL1ALDH1A1LMNA | |
| SCHEMBL21818930 | 0.80 | ATM (0.42) | HSD17B10NPC1UCHL1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250360234-A1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | US | disclosed |
| US-12383635-B2 | Radiolabelled MGL PET ligands | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-12 | — | — | US | disclosed |
| EP-4038070-B1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| CN-114555596-B | Radiolabelled MGL PET ligands | 詹森药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240100198-A1 | RADIOLABELLED MGL PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-28 | — | — | US | disclosed |
| US-9637454-B2 | Fluorine substituted cyclic amine compounds and preparation methods, pharmaceutical compositions, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MADICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-05-02 | — | — | US | disclosed |
| CN-103787954-B | Cyclic amine compound that one class fluorine replaces and preparation method thereof, pharmaceutical composition and purposes | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-20 | — | — | CN | disclosed |
| US-20150284331-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-08 | — | — | US | disclosed |
| EP-2913324-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-09-02 | — | — | EP | disclosed |
| CN-103787954-A | Fluorine-substituted cyclic amine compounds and preparation method thereof, drug composition, and uses of fluorine-substituted cyclic amine compounds | SHANGHAI INST MATERIA MEDICA | 2014-05-14 | — | — | CN | disclosed |
| EP-1592689-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| EP-1592689-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | HSD17B10 474/4885NPC1 1979/4885UCHL1 595/4885 |
| US-20240100198-A1 | RADIOLABELLED MGL PET LIGANDS | MGLL, LPL, LIPC | HSD17B10 1289/4885NPC1 470/4885UCHL1 376/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | HSD17B10 146/4885NPC1 212/4885UCHL1 481/4885 |
| US-12383635-B2 | Radiolabelled MGL PET ligands | MGLL, LPL, LIPC | HSD17B10 1289/4885NPC1 470/4885UCHL1 376/4885 |
| US-20150284331-A1 | FLUORINE SUBSTITUTED CYCLIC AMINE COMPOUNDS AND PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ACHE, BCHE, CHRM3 | HSD17B10 505/4885NPC1 625/4885UCHL1 509/4885 |
| US-20250360234-A1 | RADIOLABELLED MGL PET LIGANDS | MGLL, LPL, LIPC | HSD17B10 1329/4885NPC1 446/4885UCHL1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.